



S1 Appendix: K562 nilotinib resistance intermediates do not harbour any Bcr-Abl kinase domain mutations


DNA sequencing of the Bcr-Abl kinase domain of K562 control cells and nilotinib 4resistance intermediates was conducted and compared with the GenBank ABL reference sequence. Data demonstrate that neither the control cells nor any of the resistance intermediates contain mutations. Data were analysed using Mutation Surveyor Version 3.24 with each peak representing a DNA base (A=Adenine; C=Cytosine; G=Guanine; or T=Thymine) in the 5'-3' direction of the ABL sequence. The base number for both the reference sequence and the sequences of interest are indicated. The amino acid and corresponding residue number are also indicated. The amino acid sequences exactly match the reference sequence with no kinase domain mutations present. NIL=nilotinib
























































500

4,550

4,600

4,650


4,700

4,750

4,800

4,850

4,900



4,950

5,000

5,050

5,100

5,150


5,200


5,250


5,300


5,350


5,400
























































































































































	920)	9	925	930)	935		940	94	15	950	9	155	960	96	5	970	975	;	980	985	9:	90	995	1	000	1005
ACC	CGG	3 G /	AGC	0000	CCG	TCT	AT	AT 0	ATO	ACT	GAG	TTCA	TGA	ACCT	ACG	GGAA	CCTC	CTG	GACT	ACC	TGAG	GGGA	3 T G C	AACC	GG	CAGG	BAGG	TGA∤
ACC	CGG	3 G /	AG(000	CCG	TCT	AT	ATO	ATO	ACT	GAG	TTCA	TGA	A C C T	ACG	3 G A A	CCTC	CTG	GACT	ACC	TGAG	3 G G A	G T G C	AACC	GG	CAGG	BAGG	T G A 🖡
ACC	CGG	3 G /	AG(000	CCG	TCT	AT	AT 0	ATO	ACT	GAG	TTCA	TGA	A C C T	ACG	3 G A A	CCTC	CTG	GACT	ACC	TGAG	3 G G A	3 T G C	AACC	GG	CAGG	BAGG	T G A 🖡
ı																												- 1
3,600	ı	3,65	50	3,70		3,750	;	3,800	3,8	350	3,900	3,9	950	4,000		,050	4,100	4,1		4,200	4,25	0 4	300	4,350	4,	,400	4,450	$\overline{}$
3,600		3,65	50	3,70	310	3,750	,	3,800	3,	350 315	3,900	3,9		4,000	320		4,100	4,1	50 325	4,200	4,25	0 4	300					335
3,600 T	R	3,65 E	50 E	3,70 P		3,750 F	Y	3,800	3,8		3,900 E	3,9 F	М	4,000	320 Y	3 N	4,100 L	4,1		4,200 Y	L f	R E		N	R	Q	E	335 V
3,600 T	R R	3,65 E	50 E	3,70 P P		3,750 F F	Y Y	3,800 I I	3,i		3,900 E E	3,9 F F		4,000 T T	320 Y		4,100 L L	4,1		4,200 Y Y	L f	0 4 R E R E					E	335

